|
PubHealth.info®
(a subsidiary of
PakMed) presents scientific information mainly
based on abstracts of articles published on a variety of public health issues/topics,
particularly encompassing
population planning, disease prevention, maternal and child health,
and communicable and
non-communicable diseases (like HIV AIDS, malaria, etc) that are
affecting a significant portion of population in developing and
developed
countries. Here you can find abstracts of articles published on a variety of public health
topics under category "Contraception
(Birth Control) and Family Planning".
Contraception (birth control)
is a regimen of one or more actions, devices, or medications followed in
order to deliberately prevent or reduce the likelihood of a woman
becoming pregnant or giving birth. Therefore contraception is the
utilization of various and sundry surgical procedures, devices,
practices, agents, or drugs with the intention of preventing conception
or impregnation (pregnancy). Methods and intentions typically termed
birth control may be considered a pivotal ingredient to family
planning. Birth control is a controversial political and ethical
issue in many cultures and religions, and although it is generally less
controversial than abortion specifically. |
|
|
| CATEGORY: |
Contraception (Birth Control) and Family Planning |
| Androgenic progestins in oral contraceptives and the risk of epithelial |
| Greer JB; Modugno F; Allen GO; Ness RB |
| Obstetrics and Gynecology. 2005 Apr;105(4):731-740. |
| Oral contraceptives (OCs) have been consistently linked to reduced risk of ovarian cancer. Oral contraceptive |
| formulations display varying degrees of androgenicity. Data linking androgens to ovarian cancer suggest that OC |
| androgenicity may impact efficacy in preventing ovarian cancer. The authors investigated whether OC efficacy might |
| differ according to androgenicity by using data from a large, population-based, case-control study (the Steroid |
| Hormones and Reproductions {SHARE} Study). Detailed data on OC formulation was obtained by an in-person |
| interview for 568 cases and 1,026 controls. Multivariable logistic regression was used to assess the association of |
| OC androgenicity with ovarian cancer while controlling for the known potential confounders of age, parity, family |
| history of ovarian cancer, and tubal ligation. Androgenic and nonandrogenic OCs conferred a similar and significant |
| reduction in ovarian cancer risk (odds ratio 0.52, 95% confidence interval 0.35- 0.76 and odds ratio 0.59, 95% |
| confidence interval 0.45- 0.78, respectively). No differences in duration of use, age at first use, and time since last |
| use were found between androgenic and nonandrogenic formulations. In general, the androgenicity of an OC does |
| not alter chemopreventive efficacy. (PubHealth.info Document ID: CONT1T 63-06) |
| PubHealth.info NOTE: The author(s) of this article titled, "Androgenic progestins in oral contraceptives and the risk of |
| epithelial ovarian cancer.", is(are) Greer JB; Modugno F; Allen GO; Ness RB. The source of this article is |
| "Obstetrics and Gynecology. 2005 Apr;105(4):731-740.". This article was published in 2005 in English language(s). |
| (PubHealth.info® Document ID: CONT1T 63-06. All rights reserved with PubHealth.info) PIN: 63 |
| This article is peer-reviewed. |
|
|
|
© Copyrights PubHealth.info®,
an information portal on public health. All rights
reserved.
This page is optimized to be viewed by
Java script enabled Microsoft®
Internet Explorer 6 or later version, at screen resolution of 800 by 600 pixels. |